These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 750535)

  • 1. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of iron overload in thalassemia].
    Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to long-term deferoxamine therapy in thalassemia.
    Cohen A; Martin M; Schwartz E
    J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 16. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 18. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 19. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C; Lagos P; Langona E
    Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
    [No Abstract]   [Full Text] [Related]  

  • 20. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.